Quality of life and thinking ability in men with advanced prostate cancer
Part of Brain & nervous system, Cancer, Kidney & urinary, Mental health clinical trials.
This study looks at how treatment affects your daily life, mood, sleep, and thinking skills. It is for men starting hormone therapy combined with another drug for prostate cancer that has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have prostate cancer that has spread to other parts of the body and is sensitive to hormone therapy.
- You are about to start hormone therapy plus a second drug like abiraterone, apalutamide, or enzalutamide as part of your regular care.
- You are able to fill out questionnaires about your memory, mood, sleep, and daily life.
- You have not had cancer treatment for the spread before (except for up to 3 months of hormone therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This study tests a personalized treatment approach for men with metastatic prostate cancer that responds to hormone therapy. The trial aims to tailor your treatment based on disease risk level, potentially reducing side effects while maintaining effectiveness.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.